Enrofloxacin is a fluoroquinolone antibiotic approved for the treatment of infections in animals. Because of the side effects to consumers of animal products, the maximum residue limits (MRLs) of enrofloxacin in animal tissues for consumption are regulated. In this study, a monoclonal antibody (mAb) against enrofloxacin was prepared and characterized for the development of a direct competitive enzyme-linked immunosorbent assay (ELISA). The obtained mAb, Enro44, was highly specific for enrofloxacin and had a 50% inhibition concentration (IC 50 ) of 1.99 ng/ml in a competitive ELISA, and the limit of detection (LOD) was 0.50 ng/ml. The cross-reactivity of the mAb with other quinolones and fluoroquinolones was lower than 0.01%. The subclass of the mAb Enro44 was identified as IgG1. The antigen (Ag)-captured direct competitive ELISA using the mAb Enro44 was tested on different spiked samples, including chicken muscle, cattle milk, and cattle urine, and the assay demonstrated recoveries of 82-112%, 80-125%, and 78-124%, respectively. Furthermore, the quantitation of enrofloxacin obtained from the ELISA and from high-performance liquid chromatography (HPLC) was in good agreement, with the linear regression coefficient between 0.933 and 1.056. The cDNAs encoding a heavy-chain Fd fragment (VH and CH1) and a light chain of the mAb Enro44 were cloned and sequenced. Taken together, the results obtained reveal a potential use of this mAb in an ELISA for the detection of enrofloxacin in food samples. The information of amino acid sequence of this mAb will be useful for further modification and production of the mAb in a bioreactor.
Various antibiotics are used to treat and prevent infectious diseases in the livestock industry. Fluoroquinolones (FQs) such as enrofloxacin, becofloxacin, danofloxacin, and ofloxacin are one of the most important groups of synthetic antibacterial agents for livestock [24] . Among these FQs, enrofloxacin is one of the most commonly used antibiotics in the veterinary and aquaculture industries [18] . Because of the concerns of antibiotic residue in animal products, which may cause antibiotic resistance in pathogens, maximum residue limits (MRLs) for several antibiotics have been established in many countries to protect consumers. In the case of enrofloxacin, the MRLs were set to 100-300 ng/g, depending on the types of targeting tissue [20] . To comply with these regulations, animal products destined for human consumption must be tested for enrofloxacin residue. Various methods, such as highperformance liquid chromatography (HPLC) [7, 8] , liquid chromatography-mass spectroscopy (LC-MS) [4] , liquid chromatography-mass spectrometry/mass spectrometry (LC-MS-MS) [22] , surface plasmon resonance (SPR) [3] , enzyme-linked immunosorbent assay (ELISA) [2, 9, 24, 25] , and immunochromatography [24, 28] , have been reported to detect quinolones (Qs) and FQs. Among these methods, HPLC has been the most commonly used method to quantitatively measure residue; however, HPLC is not suitable for screening large numbers of food samples owing to its laborious process in sample preparation and the requirement for expensive equipment [18] . In contrast, ELISA-based methods are generally considered suitable for the rapid screening of enrofloxacin residue in the field [24] . Like other fluoroquinolones, enrofloxaxin needs to be monitored, and antibodies specific to each antibiotic are needed to develop antibody-based detection methods. The production of monoclonal antibodies for each antibiotic by hybridomas is tedious and labor intensive. With current recombinant DNA and antibody technologies, it is possible to manipulate immunoglobulin genes for the heterologous production of recombinant antibody fragments and for engineering the variable region of the heavy chain and light chain of the antibody molecule of interest to increase affinity [15, 19] . Because the variable region is the binding site between the antibody and the antigen, modification of the amino acid sequence in this region could affect the affinity and the specificity of the antibody. Therefore, the efficiency of an ELISA using the modified monoclonal antibody (mAb) could be improved. In addition, to obtain a large amount of mAb, the production of mAbs in in vitro cultured hybridoma cells has been studied for several decades [10] . However, animal cells are sensitive to hydrodynamic shear forces, resulting in a low number of viable cells and low mAb production [27] . Alternative production systems, such as the fermentation of antibodyproducing yeast, have been developed [5, 11, 13] . However, the genetic information of the antibody of interest is required for the heterologous production of antibody in a foreign host such as yeast. Therefore, in the present study, we produced and characterized a monoclonal antibody specific for enrofloxacin using the conventional hybridoma method, and an antigen (Ag)-captured direct competitive ELISA using the obtained antibody was evaluated. The cDNAs encoding the variable domains of the light and heavy chains were sequenced. The genetic information of the effective mAb will be useful for further large-scale antibody production.
MATERIALS AND METHODS

Immunization and Generation of Hybridomas
Female BALB/c mice aged between 8 and 10 weeks were obtained from the National Laboratory Animal Centre (Mahidol University, Bangkok, Thailand). All procedures involving the laboratory animals were approved by the Institutional Animal Care and Use Committee and conducted in accordance with the guidelines issued by Chulalongkorn University. The mice were injected intraperitoneally with 30 µg of enrofloxacin-BSA conjugate (Abkem Ibera S.L., Vigo, Spain) dissolved in phosphate-buffered saline (PBS) and an equal volume of complete Freund's adjuvant (Sigma-Aldrich, MO, USA). The animals were subsequently boosted four times with the same dose of enrofloxacin-BSA in incomplete Freund's adjuvant at threeweek intervals. The generation of hybridomas was performed using conventional methods as described elsewhere [6, 16] . In brief, isolated splenocytes were fused with the murine myeloma P3/NSI/1-Ag4-1 (ATCC TIB-18) using 50% (w/v) polyethylene glycol (PEG) (Sigma-Aldrich). The selection for hybridomas was performed in HAT media (Sigma-Aldrich) supplemented with 20% fetal bovine serum (FBS) (Invitromex, Grevenbroich, Germany). The culture supernatants were screened for antibodies against enrofloxacin by ELISA, as described below. The positive hybridomas were singlecell cloned and re-cloned by limiting dilution until monoclones were obtained. 
ELISA for Screening of Antibodies
was added. The reaction was allowed to proceed for 15 min at room temperature in the dark. The enzymatic reaction was terminated with 100 µl of 2.5 M H 2 SO 4 , and the absorbance was measured at 492 nm with a microtiter plate reader (Titertek Multiskan, CA, USA). For isotype determination, antibody isotyping kits (Sigma-Aldrich) were used.
Purification of Monoclonal Antibody
The selected monoclone was cultured in RPMI 1640 media supplemented with 10% FBS in a 200 cm 3 spinner flask. The media containing the antibody were collected and centrifuged. The antibody was purified by Protein A affinity chromatography using a step solution system (Amersham Biosciences, NJ, USA).
Syntheses of Enrofloxacin-Horseradish Peroxidase Conjugate
Enrofloxacin, 3.6 mg, was stirred gently with 1.8 mg of Nhydroxysuccinimide (Sigma-Aldrich) and 2.25 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma-Aldrich) in 1 ml of dimethylformamide for 1 h. The reaction mixture was added dropwise to the HRP solution (0.8 mg in 1.5 ml PBS) and stirred gently for 3 h at room temperature. The reactant solution was dialyzed five times against PBS at 4 o C.
Cross-Reactivity and Sensitivity of the Antibody To determine the cross-reactivity and specificity of the monoclonal antibody, an Ag-captured direct competitive ELISA was employed. Plates were coated with 100 µl of 2 µg/ml purified monoclonal antibody at 4 o C for 12-16 h and washed three times with PBST (0.05% Tween 20 in PBS). After blocking with 5% skim milk powder in PBS and washing three times with PBST, 50 µl of various concentrations of unconjugated free enrofloxacin or other compounds of interest and 50 µl of enrofloxacin-HRP conjugate were added to the plates. After incubation at 37 o C for 2 h, the plates were washed 3 times with PBST to remove the unbound antigen. The HRP assay was then performed as described above. The IC 50 was determined using the following formula: IC 50 = 50% B/B 0 , where B 0 and B are the average absorbance obtained from the Ag-captured direct competitive ELISA without and with different concentrations of the competitors, respectively. The cross-reactivity (CR) of the monoclonal antibody was calculated from the following formula: Cross-reactivity (%) = (IC 50 of enrofloxacin × 100)/IC 50 of the tested compounds. The sensitivity of the antibody in terms of the limit of detection (LOD) was calculated from the average determined concentration of 20 blank samples (B 0 ) plus three times of the standard deviation. The cross-reactivity was evaluated against related and unrelated compounds at a final concentration of 20 µg/ml. Development of Ag-Captured Direct Competitive ELISA Microtiter plates were prepared as described in the previous section. After the washing step, 50 µl of spiked samples or standard solutions and then 50 µl of enrofloxacin-HRP conjugate at a 1:6,000 dilution were added to the plates. After incubation at 37 For the HPLC analysis, the samples were further extracted twice with two volumes of dichloromethane. The upper layer of dichloromethane was pooled and evaporated at 50 o C. The residue was dissolved in 4 ml of mobile phase and filtered through a Millex-LH 0.45 mm filter (Millipore, MA, USA) prior to analysis by reverse-phase HPLC (column: C 18 ; mobile phase: water and acetonitrile; flow rate: 1 ml/min; UV detection: 275 nm).
Cloning of cDNAs Encoding a Variable Region and Constant Region of Both Heavy Chain and Light Chain
The total RNA was extracted from 5×10 6 hybridoma cells using the Tri reagent (Talron Biotech, OH, USA). The first-strand cDNA was synthesized from approximately 1 µg of RNA using a first-strand cDNA synthesis kit (Fermentas, ON, Canada). The amplifications were performed using the polymerase chain reaction (PCR). The DNA fragment encoding the variable heavy-chain (V H ) was amplified by using VHFwMH1 [23] as the forward primer and VHRwIgG1 [23] as the reverse primer, whereas the fragment encoding the variable lambda (λ) light chain (V L ) was amplified by using UmIgVLambda [1] as the forward primer and UmIgCLambda [1] as the reverse primer. The DNA fragments encoding the CH1 and variable region of the heavy chain (Fd fragment) were amplified by using a 5'-specific primer, CHFw1 (5'-GAAGTCTGGGGGAGG CTTAG-3'), designed from the known nucleotide sequence of the variable region and a 3'-reverse primer designed from the IgG1 constant region sequences from GenBank, CHRw1 (5'-GGG ATCATCCTTGCTGATGT-3'). The sequences of the DNA fragments were verified by the 5'-and 3'-specific primers, CHFw190 (5'-CACCATCTCCAGAGACAATCC-3') and CHRw342 (5'-CAGATC CAGGGGCCAGT-3'), as forward and reward primers, respectively. The 3'-RACE PCR technique was used to amplify the constant region of the λ light-chain. The total RNA from the hybridoma cell line (Enro44) was reverse transcribed to cDNA by using the T17 adapter primer (T17 AP) at 37 o C for 1 h. Subsequently, 3'-RACE was carried out with the adapter primer (AP) as the reverse primer and UmIgVLambda, a gene-specific primer, as the forward primer to synthesize the full-length DNA of the light chain. Each of the amplified DNA fragments was ligated into the pGEM vector (Promega, WI, USA) and introduced into E. coli. The plasmids were extracted and purified with the Wizard plus sv miniprep DNA purification system (Promega). DNA sequencing was performed by 1st BASE Pte Ltd. (Singapore).
Identification of Complementarity Determining Region (CDR) and Framework Sequences
The CDR and framework sequences were identified by comparison between the Enro44 Fd fragment and the IgG1, and between the Enro44 light-chain gene and the λ light-chain sequences from the database of GenBank.
The GenBank accession numbers of the sequences reported in this study are JQ048936 and JQ048937.
RESULTS AND DISCUSSION
Preparation and Characterization of the Monoclonal Antibody
After preparation and screening of the hybridomas, one monoclone (from 22 monoclones) designated Enro44, with an ability to produce the antibody that specifically recognized the unconjugated enrofloxacin, was obtained. The isotype of mAb Enro44 was identified as IgG1, and the light chain was a λ type (data not shown). After largescale production and purification, the mAb was used in an Ag-captured direct competitive ELISA to determine the detection sensitivity in terms of LOD and IC 50 . The typical working curve of the ELISA is shown in Fig. 1 . The LOD and IC 50 were 0.50 ng/ml and 1.99 ng/ml, respectively. This result indicated that the obtained mAb was sensitive enough to detect enrofloxacin at levels lower than the MRLs currently enforced (30-200 ng/ml). The sensitivity of the obtained mAb was about the same as the antibody reported by Watanabe et al. [24] that had an LOD and IC 50 of 0.1 ng/ml and 1.2 ng/ml, respectively. Another sensitive mAb was also reported with an LOD of 0.7 ng/ml, but it cross-reacted with other FQs [9] . Polyclonal antibodies raised against enrofloxacin have also been studied [2, 18] . However, a polyclonal antibody is not suitable for longterm applications owing to its batch-to-batch variation that is dependent on the antibody-producing animals [6] .
The cross-reactivity of the monoclonal antibody was also determined against various compounds. The result showed no cross-reactivity with all tested substances, including ciprofloxacin, norfloxacin, enoxacin, cinoxacin, bipemidic acid, oxolinic acid, flumequin, ofloxacin, nalidixic acid, clenbuterol, salbutamol, tetracyclin, oxytetracyclin, streptomycin, furazolidone, penicillin G, 3-amino-2-oxazolidone, and 1-aminohydantoin. The % cross-reactivity was less than 0.01% (IC 50 > 20,000 ng/ml), suggesting that the antibody was highly specific to enrofloxacin. The degree of sensitivity and specificity of an antibody determines its specific applications. Because the obtained mAb Enro44 is highly specific and sensitive, it is suitable for the development of a specific immunoassay test kit.
Sequencing Analysis of the Fd and L-Chain cDNAs
The molecular mass of the heavy chain and the light chain of mAB Enro44 analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis was found to be 64.9 kDa and 28.7 kDa, respectively (data not shown). The cDNAs coding for the heavy-chain Fd fragment of the mAb Enro44, comprising a 693 bp encoding 231 amino acid residues, and those for the light-chain, comprising a 648 bp encoding 215 amino acid residues, were cloned. The complementarity determining regions (CDRs) 1, 2, and 3 of the variable region of both heavy chain (V H ) and light chain (V L ) were identified, as depicted in Fig. 2 and 3 . CDR1 and CDR2 of the heavy-chain Fd fragment of Enro44 were similar to those of Hep27 Mab, a mAb against hepatocellular carcinoma cell lines [17] . CDR1, 2, and 3 of the variable domain of the light chain of mAb Enro44 were 95% identical to an immunoglobulin lambda chain of murine B cells with an immature phenotype (GenBank No. AAO53417.1). The sequence information of both the heavy and light chains of Enro44 allows for the modification of the possible recombinant antibody against other fluoroquinolone antibiotics in the future.
Development of Direct Competitive ELISA to Detect Enrofloxacin in Spiked Chicken Muscle, Cattle Milk, and Cattle Urine Minced chicken muscle, cattle milk, and urine were spiked with known amounts of enrofloxacin (from 5 to 100 ng/g) and extracted with a mixture of methanol and PBS at the specified ratio described in the Materials and Methods. The amount of enrofloxacin in the extracts was determined by the direct competitive ELISA. The reproducibility of the analysis using the chicken muscle and cattle milk as samples is shown in Table 1 . The % recovery (%Rev) of the chicken muscle samples was in the range of 82.3-112%, whereas the intra-variation assay and the intervariation assay were in the ranges of 2.1-11.7% and 12.3-15.4%, respectively. In the case of the cattle milk sample, the % recovery ranged between 80.4% and 124%, whereas the intra-variation and inter-variation assays ranged between 3.1-14.1% and 3.1-10.6%, respectively. For the cattle urine sample, the % recovery ranged between 80.1% and 124%, and the intra-variation and inter-variation assays ranged between 2.8-17.1% and 3.9-7.0%, respectively. The results showed no obvious systematic deviation of the assay. Furthermore, the types of matrix in the samples did not significantly affect the analysis performance. In general, the sample matrices usually have an effect on the analysis, and to reduce the influence of the biological matrices, sample dilution could be performed [24] .
Comparative Analysis of Enrofloxacin in Spiked
Samples by ELISA and HPLC To evaluate the accuracy of the analysis by ELISA using the mAb Enro44, several concentrations of enrofloxacin spiked in chicken muscle, cattle milk, and urine were analyzed by ELISA and compared with the results obtained by HPLC, the conventionally accepted method. The analyses of the two methods are shown in Table 2 . The average differences between the spiked and the measured concentrations of both methods were similar. The linear regression of the measured concentration from both methods is presented in Fig. 4 . The coefficient values of the regression were between 0.933 and 1.056, which are close to 1, suggesting that the concentrations from both analysis methods are in good agreement. This result supports the accuracy of enrofloxacin detection by ELISA previously reported by Watanabe et al. [24] . However, in his study, the concentrations obtained by HPLC were lower than those obtained by ELISA, based on the correlations, in all three types of samples (cattle milk, chicken muscle, and liver). Another comparison had been reported by Kato et al. [9] , but the developed ELISA was not specific to enrofloxacin.
In conclusion, this study reported the generation of a monoclonal antibody, Enro44, which can be used in a direct competitive ELISA to detect enrofloxacin with high specificity, sensitivity, and precision. It is sufficient for screening enrofloxacin in samples including chicken muscle, cattle milk, and urine within the range of the enforced MRL. The cDNAs of the V domain of the obtained monoclonal antibody were analyzed, which may be useful for further production of recombinant antibodies. Ag-captured direct competitive ELISA was performed by using TMB and H 2 O 2 as the substrate. The reaction was allowed to occur at room temperature for 30 min. Reverse-phase HPLC was performed by using a C 18 column and water:acetonitrile mobile phase system at room temperature, with flowrate 1 ml/min and UV detection at 275 nm.
